 |
BioWorld-International-2009-11-25
Immune Response Explains Poor Result for Vaccine Trial
Movetis Seeking €112.5M: Is End to Europe's IPO Drought Near?
No Abstract
BioWorld International Correspondent
Movetis NV is testing the mettle of European life sciences investors with the sector's first sizeable initial public offering since the first quarter of 2008.
With a European product launch imminent, the company offers a far less risky proposition than most, however.
Oxagen Raises $26M to Boost Midstage Asthma Compound
LONDON - The flood of new money into European biotechs continued as Oxagen Ltd. announced the completion of a £16 million (US$26.4 million) third-round funding, with new investor Novartis Venture Funds leading the round. (BioWorld International)